D-dimer Corrected for Thrombin and Plasmin Generation is a Strong Predictor of Mortality in Patients with Sepsis
Overview
Authors
Affiliations
Background: D-dimer (DD) is the most used fibrin-related marker and has been proposed, either alone or in combination with other variables, as prognostic factor in patients with sepsis. However, DD generation depends on both coagulation and fibrinolysis, meaning that it may give false negative results in conditions associated with marked fibrinolytic inhibition such as sepsis. In this study, we tested whether correction of DD for thrombin and plasmin generation could improve its prognostic significance in septic patients.
Material And Methods: We performed a nested study in 269 septic patients from the ALBIOS trial. DD, prothrombin fragment 1+2 (F1+2) and plasmin-antiplasmin complex (PAP) were assayed at day 1. Corrected DD (DD) was calculated by the formula DD×PAP/F1+2, such that the lower the DD the greater the imbalance in favour of fibrin formation over fibrin lysis, and vice-versa. Primary outcome was 90-day mortality.
Results: DD showed a J-shaped relationship with mortality, which was highest in the first DD tertile (low fibrinolysis), intermediate in the 3 (high fibrinolysis), and lowest in the 2 (balanced fibrinolysis), suggesting an increased risk whenever the coagulation-fibrinolysis balance is tilted (p<0.0001). Neither DD, nor PAP or F1+2 showed a comparable association with mortality. DD was an independent prognostic factor in multivariable Cox models and significantly improved risk stratification (cNRI≥0.28). Finally, by combining DD and SOFA tertiles, we developed a score with high discriminatory power.
Discussion: DD is a good marker of the in vivo coagulation-fibrinolysis balance and displays a prognostic value in sepsis much higher than DD.
A Nomogram-Based Model for Predicting the Risk of Severe Acute Cholangitis Occurrence.
Xu J, Xu Z, Zhuang J, Yang Q, Zhu X, Yao J Int J Gen Med. 2023; 16:3139-3150.
PMID: 37521070 PMC: 10386866. DOI: 10.2147/IJGM.S416108.
Monitoring the Coagulation Profile of COVID-19 Patients Using Standard and ClotPro Hemostasis Tests.
Milic D, Lazarevic M, Vukovic N, Kamenov A, Peric V, Golubovic M Medicina (Kaunas). 2023; 59(7).
PMID: 37512014 PMC: 10386453. DOI: 10.3390/medicina59071202.
Li J, Wang Y, Luo J, Yin Z, Huang W, Zhang J Sci Rep. 2023; 13(1):10849.
PMID: 37407641 PMC: 10322897. DOI: 10.1038/s41598-023-37907-2.
Sotos K, Goggs R, Stablein A, Brooks M Front Vet Sci. 2023; 10:1104602.
PMID: 36876005 PMC: 9978197. DOI: 10.3389/fvets.2023.1104602.
Emerging Biosensing Technologies towards Early Sepsis Diagnosis and Management.
Bonini A, Carota A, Poma N, Vivaldi F, Biagini D, Bottai D Biosensors (Basel). 2022; 12(10).
PMID: 36291031 PMC: 9599348. DOI: 10.3390/bios12100894.